Related Experiment Video

Updated: Oct 15, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

New clinical trials for the treatment of neuroendocrine tumors

E Bajetta1, E Bichisao, S Artale

  • 1Unit of Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)
|August 10, 2000
PubMed

Insights

Neuroendocrine tumors (NETs) show increasing interest in oncology. While surgery is preferred, new long-acting formulations of somatostatin analogues like lanreotide and octreotide show promising results for NET treatment.

Area of Science:

  • Oncology
  • Endocrinology
  • Gastroenterology

Background:

  • Neuroendocrine tumors (NETs) are gaining attention in oncology, with recent data suggesting shifts in carcinoid tumor proportions.
  • Despite being indolent and difficult to diagnose, the true incidence of NETs may be underestimated.
  • Surgery is the primary treatment, but complete cure is challenging, and cytotoxic chemotherapy offers modest benefits for high-grade NETs.

Purpose of the Study:

  • To review the current landscape of neuroendocrine tumor management.
  • To highlight recent advancements in hormonal therapy, specifically long-acting somatostatin analogues.
  • To discuss challenges in conducting clinical trials for neuroendocrine tumors.

Main Methods:

  • Review of recent clinical trials and literature on neuroendocrine tumors.
  • Focus on long-acting formulations of somatostatin analogues: lanreotide prolonged-release (PR) and octreotide long-acting release (LAR).
  • Discussion of diagnostic challenges and the role of biological markers.

Main Results:

  • Recent trials using long-acting formulations of lanreotide (30 mg every 2 weeks) and octreotide (10, 20, or 30 mg every 28 days) demonstrate very promising outcomes.
  • These formulations represent a significant advancement in the hormonal treatment of neuroendocrine tumors.
  • The study acknowledges the difficulty in conducting new clinical trials due to methodological and clinical complexities.

Conclusions:

  • Long-acting somatostatin analogues (lanreotide PR and octreotide LAR) offer promising therapeutic options for neuroendocrine tumors.
  • Further investigation into biological markers is warranted before widespread clinical adoption.
  • Despite treatment advances, challenges in clinical trial design and achieving complete cures persist in NET management.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...